Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VACIMRA: Methotrexate Timing and Pneumococcal Vaccination in Rheumatoid Arthritis
NCT01942174Phase 3Completed
- Sponsor
- CHU Montpellier
- Start
- Sep 2013
- Primary completion
- Aug 2018
- Modality
- Split/Subunit Vaccines
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of pneumococcal 13-valent conjugate vaccine in pneumococcal infection (2 arms), sponsored by CHU Montpellier. Primary endpoint: Rate of immunological positive answer to Prevenar 13 at 1 month. Started Sep 2013; status: completed.
02
Drugs
pneumococcal 13-valent conjugate vaccine
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT01942174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01942174.